Literature DB >> 30648505

Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications.

Hassan Dianat-Moghadam1,2,3,4, Ladan Teimoori-Toolabi2.   

Abstract

Fibroblast growth factors (FGFs) are pleiotropic molecules exerting autocrine, intracrine and paracrine functions via activating four tyrosine kinase FGF receptors (FGFR), which further trigger a variety of cellular processes including angiogenesis, evasion from apoptosis, bone formation, embryogenesis, wound repair and homeostasis. Four major mechanisms including angiogenesis, inflammation, cell proliferation, and metastasis are active in FGF/FGFR-driven tumors. Furthermore, gain-of-function or loss-of-function in FGFRs1-4 which is due to amplification, fusions, mutations, and changes in tumor-stromal cells interactions, is associated with the development and progression of cancer. Although, the developed small molecule or antibodies targeting FGFR signaling offer immense potential for cancer therapy, emergence of drug resistance, activation of compensatory pathways and systemic toxicity of modulators are bottlenecks in clinical application of anti-FGFRs. In this review, we present FGF/FGFR structure and the mechanisms of its function, as well as cross-talks with other nodes and/or signaling pathways. We describe deregulation of FGF/FGFR-related mechanisms in human disease and tumor progression leading to the presentation of emerging therapeutic approaches, resistance to FGFR targeting, and clinical potentials of individual FGF family in several human cancers. Additionally, the underlying biological mechanisms of FGF/FGFR signaling, besides several attempts to develop predictive biomarkers and combination therapies for different cancers have been explored. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Fibroblast growth factor; cancer; drug resistance; fibroblast growth factor receptor; signal transduction; targetedzzm321990therapy.

Year:  2019        PMID: 30648505     DOI: 10.2174/1389450120666190112145409

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  6 in total

1.  AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer.

Authors:  Abdulmelik Aytatli; Neslisah Barlak; Fatma Sanli; Hasan Onur Caglar; Betul Gundogdu; Arzu Tatar; Michael Ittmann; Omer Faruk Karatas
Journal:  Cell Oncol (Dordr)       Date:  2021-11-27       Impact factor: 6.730

Review 2.  2b or Not 2b: How Opposing FGF Receptor Splice Variants Are Blocking Progress in Precision Oncology.

Authors:  Richard J Epstein; Li Jun Tian; Yan Fei Gu
Journal:  J Oncol       Date:  2021-04-30       Impact factor: 4.375

3.  An FGFR/AKT/SOX2 Signaling Axis Controls Pancreatic Cancer Stemness.

Authors:  Mei-Yu Quan; Qiang Guo; Jiayu Liu; Ruo Yang; Jing Bai; Wei Wang; Yaxin Cai; Rui Han; Yu-Qing Lv; Li Ding; Daniel D Billadeau; Zhenkun Lou; Saverio Bellusci; Xiaokun Li; Jin-San Zhang
Journal:  Front Cell Dev Biol       Date:  2020-05-07

4.  miR-877-3p inhibits tumor growth and angiogenesis of osteosarcoma through fibroblast growth factor 2 signaling.

Authors:  Mingji Chen; Zhi Li; Lei Cao; Chi Fang; Rufeng Gao; Chao Liu
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

5.  An algorithm to quantify intratumor heterogeneity based on alterations of gene expression profiles.

Authors:  Mengyuan Li; Zhilan Zhang; Lin Li; Xiaosheng Wang
Journal:  Commun Biol       Date:  2020-09-11

Review 6.  Roles for growth factors and mutations in metastatic dissemination.

Authors:  Nishanth Belugali Nataraj; Ilaria Marrocco; Yosef Yarden
Journal:  Biochem Soc Trans       Date:  2021-06-30       Impact factor: 5.407

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.